The cardiac tumor is an abnormal growth of tissues in the heart or heart valves. Cardiac tumors are rare and can be cancerous or noncancerous. Tumors that originate in the heart and are bound to stay there are called primary tumors. On the contrary, tumors that grow in some other part of the body and spreads to the heart i.e. metastasize are called secondary tumors.
The prevalence of primary cardiac tumors is 0.001-0.03%. Secondary tumors are 20-40 found to be more common than primary tumors because 15% of patients with any form of cancer exhibit metastases to the heart. According to the WHO, cancer is the leading cause of death worldwide, accounting for 8.8 million deaths in 2015. Globally, lung cancer accounted for 1.69 million deaths and subsequently, breast cancer caused 571,000 deaths in 2015.
The global heart tumor market is expected to grow at a CAGR of approximately 7.1% during the forecast period 2017-2023.
Cardiac neoplasm is a rare pathological condition associated with non-specific signs and symptoms and must be considered while treating conditions like cardiac arrhythmia, ischemic syndromes, and Hiss-Purkinje conduction system dysfunction. Sometimes drugs can be injected into the pericardial area of the heart to slow the tumor growth. During the surgery, the surgeon removes the tumor and the tissue around it to reduce the risk of tumor recurrence. Increasing incidence of cancer metastasis and high technological advancement with the rising adoption promotes the growth of the heart tumor market.
The global heart tumor consists of regions namely the America, Europe, Asia Pacific, and the Middle East Africa.
North America dominates the global heart tumor market. The Asia Pacific region is growing at a higher rate than any other region globally. The demand for diagnostic outpatient surgeries is increasing, which in turn, increasing the growth of the Asia Pacific heart tumor market.
In India, increasing number of hospitals and healthcare services, availability of low cost of raw material, and better access to labor drive the growth of this market. Australia and the Republic of Korea are experiencing slow growth in the imaging devices and heart tumors market.
The heart tumor market is segmented on the basis of type, diagnosis, treatment.
On the basis of the type, the market is segmented into the primary tumor and secondary tumor. The primary tumors are divided into benign and malignant. The benign tumor is further categorized into myxoma, papillary heart tumors, fibromas, rhabdomyomas, angioma, and lipomas. The malignant tumors are divided into rhabdomyosarcoma, mesenchymomas, neurosarcoma, fusiform cell tumors, malignant heart hemangioma, and lymphosarcoma. The secondary tumors are categorized into metastatic and by contiguity. The metastatic secondary tumors are divided into hematogenic and lymphatic and the contiguity is sub-categorized into mediastinal tumors, lung tumors and oesophageal, or cardia tumor.
On the basis of diagnosis, the market is classified into Echocardiogram, Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI), Radionuclide imaging, Positron Emission Tomography (PET) Scan, myocardial biopsy, cardiac catheterization, electrophysiology test.
On the basis of the treatment, the market is classified as surgery, chemotherapy, radiation therapy. Furthermore, the surgery is further categorized into open heart surgery, minimally invasive surgery, and heart transplant surgery
Some of key the players in the global heart tumor market are Tomtec Imaging Systems GmBh, Koninklijke Philips N.V., Siemens Healthineers, Circle Cardiovascular Imaging Inc., Toshiba Corporation, Shimadzu Corporation, CardioComm Solutions Inc., Integer Holdings Corporation, Pie Medical Imaging, HeartSciences, 3mensio Medical Imaging, and eMedica, S.L.